NASD · Healthcare · Biotechnology · USA
Tenax Therapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Tenax Therapeutics is a development-stage pharmaceutical company conducting clinical trials to evaluate levosimendan and imatinib as treatments for cardiopulmonary diseases, particularly a form of pulmonary hypertension affecting heart failure patients. Both drug candidates have been approved in other indications and prescribed globally with established safety profiles. The company employs a clinician-driven approach to develop therapies addressing unmet medical needs.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Tenax Therapeutics Inc stock.
Not valued: We cannot value this company yet.
137 more in this industry show a wider margin of safety.
We do not publish a verdict on TENX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-16 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.